Piramal Pharma Share Price in Focus After US FDA Inspection Update

Piramal Pharma Limited has been in focus on Wednesday following updates on a recent US FDA inspection. On February 19, 2025, Piramal Pharma share price opened at ₹190.00, down from its previous close of ₹197.66. However, at 11:10 AM, the share price of Piramal Pharma was trading at ₹202.17, up by 2.28% on the NSE. The stock price touched its day’s high so far at ₹203.79.

US FDA Inspection at Turbhe Facility

Piramal Pharma informed the stock exchanges that the US Food and Drug Administration (FDA) conducted a General Good Manufacturing Practice (GMP) inspection at its Turbhe facility from February 11 to February 17, 2025. At the end of the inspection, the FDA issued a Form-483 with six observations. The company clarified that these observations were related to procedural improvements and not data integrity issues.

Piramal Pharma is preparing a detailed response to the observations and is confident of resolving them within the stipulated timeline. The company reiterated its commitment to maintaining high compliance standards.

9M FY 2025 Financial Highlights

For 9M FY 2025, Piramal Pharma reported a 14% YoY growth in revenue from operations, primarily driven by strong performance in the CDMO business. EBITDA grew by 20% YoY, supported by operating leverage, cost optimisation initiatives, and a superior revenue mix. The company maintained a stable net-debt to EBITDA ratio of 2.8x while upholding its best-in-class quality track record, with no pending observations at any US FDA-inspected sites.

In a significant sustainability move, Piramal Pharma converted the coal-fired steam boiler at its Digwal facility to operate on biomass briquettes, a carbon-neutral fuel source, reducing ~24,000 tCO2e GHG emissions annually, about 17% of its total emissions.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.